# Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations for $122.5M

- Link: https://www.thailand-business-news.com/pr-news/bora-group-to-acquire-macrogenics-gmp-manufacturing-operations-for-122-5m
- Published: 2026-05-12T12:00:00+07:00
- Author: Media OutReach

#### _Securing Maryland-Based Drug-Substance Facility and Existing Commercial Orders to Scale the Group’s Integrated Technology Platform_

HONG KONG SAR – [Media OutReach Newswire](https://www.media-outreach.com/) – 12 
May 2026 – Bora Pharmaceuticals (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY)
today announced that its Board of Directors has approved the acquisition of the 
GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc. (
NASDAQ: MGNX), for total consideration of US$122.5 million, subject to customary
working capital adjustments, and a contingent consideration of up to $5 million 
based on future customer orders. The transaction includes a biologics drug substance
manufacturing facility located in Rockville, Maryland and an associated warehousing
center in Frederick, Maryland. Upon closing of the acquisition, the Company will
sign a long-term CDMO Service Agreement with MacroGenics.

 Following closing, Bora Group intends to leverage the Rockville Site in cooperation
with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise
under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities,
this is expected to scale the Group’s end-to-end biologics platform.

 The Rockville facility has operated as an outsource manufacturing partner since
2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors
and fully integrated QC and analytical laboratories and has been inspected by both
the U.S. FDA and Japan’s PMDA. From the transaction, Bora is expected to assume 
a substantial backlog for the size of its Bora Biologics CDMO business, including
commercial-stage monoclonal antibody programs, clinical-stage programs, and a strong
project pipeline. Commercial manufacturing currently accounts for more than half
of the site’s revenue.

 “This acquisition marks a pivotal step in strengthening Bora’s integrated biologics
CDMO platform in the United States”, said Bobby Sheng, Chairman and CEO of Bora 
Group. “With the addition of the Rockville site, Bora Biologics total drug substance
capacity would be 20,000-liter (SUB) and Bora Group will integrate our in-house 
DS (Drug Substance) and DP (Drug Product) capabilities and network investments over
the next 12 to 18 months to offer global biotech customers a seamless offering allowing
customers to advance programs from development through commercial supply with one
single partner.”

 **Bora’s Board of Directors has authorized the Chairman** to finalize the transaction
in line with market conditions and the regulatory environment. For the year ended
December 31, 2025, MacroGenics reported contract manufacturing revenue of $52.6 
million. 
Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

#### About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.
OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing
to Better Health All Over the World”. Operating under a “Dual Engine” model that
integrates CDMO and commercial expertise, we empower pharmaceutical and biotech 
partners to optimize product development, accelerate launches, and scale supply 
to meet global patient needs. At the same time, we actively broaden R&D and sales
infrastructure, focusing on niche and rare disease markets to improve patients’ 
quality of life.

 By investing in talent, infrastructure, and biologics expansion, Bora continues
to transform operations and achieve sustainable growth. Committed to making success“
certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

 For more, please visit: 
 [https://www.bora-corp.com](https://www.bora-corp.com/)
[https://www.boracdmo.com](https://www.boracdmo.com)

 **Disclaimer:** 
 This document and the accompanying information may contain forward-
looking statements. All statements regarding the company’s future business operations,
potential events, and prospects (including but not limited to forecasts, targets,
estimates, and operational plans) are considered forward-looking statements unless
they refer to factual occurrences. Forward-looking statements are subject to various
factors and uncertainties that may cause significant differences from actual results,
including but not limited to price fluctuations, actual demand, exchange rate variations,
market share, competitive conditions, changes in the legal, financial, and regulatory
framework, international economic and financial market conditions, political risks,
cost estimates, and other risks and variables beyond the company’s control. These
forward-looking statements are based on current predictions and assessments, and
the company disclaims any responsibility for future updates.

![](//track.media-outreach.com/index.php/WebView/464333/36955)

**Source** : [Bora Group to Acquire MacroGenics’ GMP Manufacturing Operations for $122.5M](https://www.media-outreach.com/news/hong-kong-sar/2026/05/12/464333/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://i0.wp.com/www.thailand-business-news.com/wp-content/
uploads/2025/04/media-outreach-20025.png?ssl=1)
